about
Infection risk in patients on multiple sclerosis therapeutics.The impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myelomaDo patients with recurrent episodes of campylobacteriosis differ from those with a single disease event?Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas.Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy.The occurrence and prevention of foodborne disease in vulnerable people.Infection and Lupus: Which Causes Which?Is There a Role for Opportunistic Infection Prophylaxis in Pemphigus? An Expert Survey.Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.High-resolution CT findings of patients with pulmonary nocardiosis.Methods of evaluating immunotoxicity.Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based RegimensThe Use of In Vitro Systems for Evaluating Immunotoxicity: The Report and Recommendations of an ECVAM Workshop.Present and future of in vitro immunotoxicology in drug development.The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia.Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus.Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy.Antibody replacement therapy in primary antibody deficiencies and iatrogenic hypogammaglobulinemia.Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy.Disseminated nocardiosis during systemic steroid therapy for the prevention of esophageal stricture after endoscopic submucosal dissection.Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.Impact of anti-inflammatory drug consumption in peritonsillar abscesses: a retrospective cohort studyInsights from the predicted interactions of plant derived compounds to the gluco-corticoid receptor as an alternative to dexa-methasone.Ex vivo stimulation of whole blood as a means to determine glucocorticoid sensitivityCryptococcus infection in a non-HIV patient: a case report.Incidence of infections in patients with giant cell arteritis: a cohort study.Central Nervous System Infections Associated with Immunosuppressive Therapy for Rheumatic Disease.Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication).Dexamethasone as endocrine disruptor; type I and type II (anti) oestrogenic actions on the ovary and uterus of adult Wistar rats ()
P2860
Q30908652-508FE692-50A4-40F8-BE28-286FC124369AQ33562719-C5E40ECB-7364-46CC-B491-E6FBB3FFCEF9Q33791332-3B6F3A1D-9AC6-4D33-AFA7-9AC4F3F310DFQ34628416-50748DFC-26E3-4663-8CCD-A41706DD6303Q35048101-7C419341-E4B0-4748-88A4-FB65FD85A744Q35173590-B70D897F-B180-4AB3-80B5-402C4869AB79Q35948285-EE176F46-1FE1-4780-81F6-0A9E8BA8505AQ36186430-E996A785-34F3-4C76-BCFB-4F2A54F51DB0Q36223905-5AC188B3-47F3-4CD2-94A2-733D8FA48D69Q36424381-9A4FBFAE-8A92-4471-BAA6-74DFA017CAE5Q36546265-8627E19F-8B99-4F27-BF12-E85E55505CA9Q36735810-AE0612A1-B846-4D2E-AD76-04A140F7724CQ37311022-FCD596E7-B916-433A-9147-AFAB913B9362Q37782071-7AC97EF8-ED92-43B7-8C94-3BC7FCF9A6CEQ38012165-07559352-8DFD-4278-923C-E214EB922643Q38182646-7DAADD20-2949-4F61-8A06-A4ECC6B581F2Q38286988-803E60C7-6F45-4F1D-9FD3-E1BCCAB229FFQ38548417-9E99DCE8-3422-4685-9E58-06518172E450Q40150284-25740D93-F710-48F1-8412-21235D153612Q40205012-E27ABC4F-D129-4DD5-BFB0-9F4A80A18F15Q40251294-9415D6F9-1302-43B0-BDB5-FCCBD1FE6D7BQ40568948-CF39A498-719F-4559-8F22-98F21B99CAFEQ42239837-FA60959B-9773-4220-90CF-C18B4A51F794Q42321739-D73B184C-F19F-4B8F-908B-DC85DF604C41Q43088123-68ACDE78-9735-4999-89FD-EFB91FE3F41FQ45344678-4D6F5BD5-31D6-4F66-B641-4552C0AC7ED8Q46339578-6BD389B9-D1DB-4F40-BE57-D342E95357B4Q54216562-EE3AB801-1B27-4FDD-BB35-E158DC0CAD07Q58790395-07AA1047-E74C-41EA-9F60-17E240C1A1F0
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Infections associated with steroid use.
@ast
Infections associated with steroid use.
@en
Infections associated with steroid use.
@nl
type
label
Infections associated with steroid use.
@ast
Infections associated with steroid use.
@en
Infections associated with steroid use.
@nl
prefLabel
Infections associated with steroid use.
@ast
Infections associated with steroid use.
@en
Infections associated with steroid use.
@nl
P2093
P1476
Infections associated with steroid use.
@en
P2093
P304
423-32, viii
P356
10.1016/S0891-5520(05)70154-9
P577
2001-06-01T00:00:00Z